Drug intelligence / Profile preview

MCTL001

Development stage: Unknown
Lead developer: Hebei Bio-High Technology Development
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Intravenous

Overview

MCTL001 (MCTL® Multi-Target Anti-Tumor Cell Drug) is an autologous cell therapy developed by Hebei Bio-High Technology Development. It consists of a combination of dendritic cells (DCs) and multi-target cytotoxic T lymphocytes (CTLs). The therapy is designed to recognize and attack tumor cells by targeting over 322 tumor-specific cluster targets across 19 different types of solid tumors, including lung, pancreatic, colorectal, and gastric cancers. MCTL001 is classified as a Class 1 new drug in China and is currently in the NDA filing stage. The production of clinical samples for the therapy has been conducted in collaboration with Jiuzhou Pharmaceutical, and clinical trials have been conducted at major Chinese medical institutions including Peking Union Medical College Hospital and PLA General Hospital.

Brand names: MCTL
Other names: MCTL Multi-Target Anti-Tumor Cell Drug多靶点抗肿瘤细胞制品

Beyond the preview

Go deeper on MCTL001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCTL001.

Explore the full profile